Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,745 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biomarker blood draw Clear all
Terminated No phase listed Observational

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

NCT01141218
View directory record Official record
Conditions
Lung Cancer
Interventions
internet-based protocol and physician referral
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis

NCT01299961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 29, 2026, 6:37 PM EDT
Terminated Not applicable Interventional Results available

Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery

NCT00984490
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

NCT02613923
View directory record Official record
Conditions
Breast Cancer, Sleep
Interventions
GO! To Sleep, Sleep information, Blood Draw, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), SF-12 quality of life survey
Behavioral · Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

NCT05437588
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideas, Suicide, Attempted, MDD, Depression, Depression, Teen, Depression and Suicide, Depression in Adolescence, Suicide
Interventions
Genetic testing
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 24 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acute Cryotherapy on Musculoskeletal Function and Biomarkers

NCT07211412
View directory record Official record
Conditions
Exercise Induced Muscle Damage, Cryotherapy
Interventions
Cryotherapy, Eccentric exercise-induced muscle damage
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

NCT00985036
View directory record Official record
Conditions
Glioma, Meningioma
Interventions
Blood test
Procedure
Lead sponsor
Marquette General Health System
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Marquette, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

NCT00729157
View directory record Official record
Conditions
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
Interventions
Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Ziv-Aflibercept
Radiation · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

NCT00064129
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting No phase listed Observational

A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions

NCT02647177
View directory record Official record
Conditions
Pancreatic Cystic Lesions
Interventions
Pancreatic Cyst Aspiration
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT02805075
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy
Interventions
Fructooligosaccharide, Laboratory Biomarker Analysis
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting No phase listed Observational

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

NCT06305728
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
89Zr-DFO-HuMab-5B1 immunoPET, HP MRI, Blood assay
Diagnostic Test · Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Apnea and Obesity Affects on Morphine Pharmacokinetics

NCT02732795
View directory record Official record
Conditions
Pediatric Sleep Apnea, Obesity, Morphine Metabolism
Interventions
Morphine pharmacokinetic evaluation
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

NCT01842139
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 29, 2026, 6:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

NCT02447627
View directory record Official record
Conditions
Healthy, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

NCT03442088
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 29, 2026, 6:37 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms

NCT04379024
View directory record Official record
Conditions
Focus of Study is Healthy Women at Risk for Breast Cancer
Interventions
DUAVEE 0.45Mg-20Mg Tablet
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 29, 2026, 6:37 PM EDT
Terminated Phase 1 Interventional

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00049088
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a B12 Vitamin to Increase Energy and Focus

NCT05517005
View directory record Official record
Conditions
B12 Deficiency Vitamin, Energy Supply; Deficiency, Mood
Interventions
Hype Bites Supplement
Dietary Supplement
Lead sponsor
Sourse
Industry
Eligibility
24 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 29, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00310024
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, vorinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 29, 2026, 6:37 PM EDT
Completed No phase listed Observational

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

NCT02808494
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Newark, Delaware • Boston, Massachusetts • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

NCT07128680
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Dietary Supplement · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting No phase listed Observational

Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool

NCT05311046
View directory record Official record
Conditions
Sepsis
Interventions
Pediatric sepsis screening tool (either algorithmic or manual)
Diagnostic Test
Lead sponsor
Computer Technology Associates, Inc.
Industry
Eligibility
3 Months to 45 Years
Enrollment
12,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 6:37 PM EDT